Melasma-like hyperpigmentation: A rare side effect of imatinib mesylate
Imatinib mesylate is an oral tyrosine kinase inhibitor used chiefly to treat chronic myeloid leukemia. In the literature, hypopigmentation is a commonly reported side effect of imatinib therapy; however, the cases of melasma-like hyperpigmentation due to imatinib have also been sparingly reported. W...
| Published in: | Journal of the Scientific Society |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Subjects: | |
| Online Access: | http://www.jscisociety.com/article.asp?issn=0974-5009;year=2023;volume=50;issue=2;spage=275;epage=277;aulast=Agrawal |